Patient survival subgroups post TARE have not been clearly defined.<h4>Aims</h4>1.2.To identify prognostic factors in patients treated with TARE.<h4>Methods</h4>1.3.Non-surgical HCC patients (n=116) were treated with TARE and prospectively followed for survival and changes in blood parameters relating to inflammation and tumor indices.<h4>Results</h4>1.4.Baseline parameters with the highest hazard ratios (HR>2) for survival were C-reactive protein, alpha-fetoprotein (AFP), maximum tumor diameter (MTD) and PVT. The gene discussed is AFP; the disease is hepatocellular carcinoma.